Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Scrip 100 - R&D

Scrip 100: R&D Paths Of Top 50 Pharma

How has R&D spending in the pharmaceutical industry changed over the last decade? While the R&D collective picture for Big Pharma may not have changed much, individual company stories differ markedly.

Research & Development Research and Development Strategies Companies

A Bird’s Eye View Of The Rare Disease R&D Landscape

The number of drugs in development for rare diseases have increased by 56%, with the number of rare diseases on the development map also increasing by 23% in just three years, demonstrating ongoing interest and seemingly increased enthusiasm for research within these areas of high unmet needs.

Research & Development Rare Diseases BioPharmaceutical

Philanthropic Giving: Upsetting The Apple Cart Or Plugging The Pipeline?

Facebook inventor Mark Zuckerberg grabbed headlines across the globe this year when he and wife Priscilla Chan announced a $3bn initiative with one momentous goal: to cure all disease. The initiative has released few details, but the pledge of $3bn from a technology business owner into disease research has sparked curiosity and concern.

Strategy Digital Health BioPharmaceutical
Advertisement
UsernamePublicRestriction

Register

Advertisement